McKesson completes Vantage Oncology, Biologics acquisitions

SAN FRANCISCO — McKesson announced Monday that it had completed its acquisitions of both Biologics and Vantage Oncology for $1.2 billion. 

 

McKesson, when announcing the acquisitions in February, noted that they would increase the scale of its specialty pharmaceutical distribution, its oncology-focused pharmacy offerings, manufacturer and payer solutions and the scope of community-based oncology and practice management services for providers and patients. 

 

“McKesson is committed to the success of our community oncology partners and customers and we believe the acquisitions of Vantage and Biologics complement our holistic approach to providing best–in-class care for oncology patients,” McKesson chairman and CEO John Hammergren said when the deal was announced. 

 

Vantage Oncology adds more than 50 cancer centers to McKesson, as well as its comprehensive oncology management service model and a practice management model that it operates through joint ventures, sharing profits with partner physicians and hospitals. Biologics adds to the company its high-touch specialty pharmacy model, which provides controlled dispensing channels, including rapid and traceable pharmaceutical delivery solutions, increased analytics, and services for oncology patients, providing seamless care management.